It is estimated that migraines are the third most prevalent illness in the world, affecting 39 million people in the U.S. and one billion globally. This debilitating condition is known to impact a patient’s quality of life, with a reported 90 percent of sufferers being unable to function normally while experiencing symptoms. Compared to patients with episodic migraine, those with chronic migraine have worse socioeconomic status, reduced health-related quality of life, increased headache-related burden, and greater psychiatric and medical comorbidities.
To better help these patients and the specialists who treat them, Therigy has added a dedicated migraine care plan within TherigySTMTM, a patient-centered therapy management solution. This new disease state care plan will better assist specialty pharmacies in clinically managing patients who are prescribed this new drug therapy to treat or prevent chronic and episodic migraine headaches.
TherigySTM's Migraine Care Plan includes:
- clinical assessments
- reporting capabilities